Citius Oncology (CTOR) Intangibles (2024 - 2026)

Citius Oncology (CTOR) posted quarterly Intangibles of $73.4 million for Q1 2026, up 0.79% quarter-over-quarter from $72.8 million in Q4 2025.

Citius Oncology (CTOR) Intangibles (2024 - 2026) Analysis & Trends

Citius Oncology (CTOR) has reported Intangibles for 3 consecutive years, with $73.4 million the latest figure, recorded in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Intangibles (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	3.45 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	918.00 Mn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	21.28 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	-
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	13.68 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	2.23 Bn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	3.20 Bn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	1.12 Bn
10	Citius Oncology	80.25 Mn	80.25 Mn	1.00 Mn	73.40 Mn

Download Data